By Nigel Somerville, the Deputy Sheriff of AIM | Thursday 30 September 2021
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Oh dear, oh dear, oh dear. AIM-listed Advanced Oncotherapy has announced its interims to June: the numbers are predictably dreadful but the killer is surely the indication of a delay to the completion of the company’s first proton therapy LIGHT system.